Arbutus Biopharma (ABUS) Tops Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 5, 2022 7:30 AM EDTKey milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track
Well positioned financially with a projected cash runway into the second quarter of 2024
Conference Call and Webcast Today at 8:45 AM ET
WARMINSTER, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its first quarter 2022... More
